Ibrutinib

[otw_shortcode_tabslayout tabs=”8″ tab_1_title=”Overview” tab_1_content=”Ibrutinib is an antineoplastic drug. It has anti-sleeve cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and Walden’s macroglobulinemia.” tab_2_title=”Indications” tab_2_content=”1. For the treatment of condylomatous lymphoma (MCL) that has received at least 1 prior therapy. 2. For the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 3. Used alone for the first-line treatment of Waldenstrom’s macroglobulinemia (WM) in patients who have received at least 1 prior therapy or are not candidates for chemoimmunotherapy. 4. Used in combination with rituximab for the treatment of WM. ” tab_3_title=”Dosage” tab_3_content=”1. MCL: Administer orally at the recommended dose of 560 mg once daily until disease progression or intolerable toxicity occurs. 2. CLL/SLL: Oral administration at a recommended dose of 420 mg once a day until disease progression or intolerable toxicity occurs. WM: Administered orally at a recommended dose of 420 mg once daily until disease progression or intolerable toxicity occurs. When used in combination with rituximab, it is recommended that ibrutinib be given prior to rituximab administration. ” tab_4_title=”Precautions” tab_4_content=”1. If surgery is required, the pros and cons of stopping the drug for 3 to 7 days before and after surgery should be weighed according to the type of surgery and risk of bleeding. 2. Women of childbearing potential must use highly effective contraceptive measures during and for 1 month after stopping the pill. Women using hormonal contraception must also use an additional barrier method of contraception (e.g., condom use). 3. Male patients should avoid childbirth during and for 3 months after discontinuation of the drug. 4. Ibrutinib can cause fatigue and dizziness and caution should be exercised when driving or operating machinery. ” tab_5_title=”Contraindications” tab_5_content=”Do not use if you are allergic to ibrutinib.” tab_6_title=”Adverse Reactions” tab_6_content=”Common side effects after use of the drug include bleeding (may manifest as bruising), infection, rash, fatigue, skeletal muscle pain, edema, nausea, diarrhea, constipation, abdominal pain, vomiting, decreased appetite, cough, difficulty breathing, and fever.” tab_7_title=”Interactions” tab_7_content=”1. Food Consumption of grapefruit and lime during medication may increase the blood level of ibrutinib and may cause side effects. Please avoid eating grapefruit, lime and their products during the drug administration. (1) Combining ibrutinib with antiplatelet agents (e.g. aspirin) and anticoagulants (e.g. warfarin) may increase the risk of bleeding, so please be careful when combining them. (2) Combination of ibrutinib with cytochrome P450 (CYP) 3A inhibitors (e.g. fluconazole, clarithromycin, etc.) may increase the efficacy and side effects of the drug, so please combine with caution. (3) Combination of ibrutinib with potent CYP3A-inducing drugs (e.g. carbamazepine, rifampin, etc.) may reduce the efficacy of ibrutinib, so please combine with caution. ” tab_8_title=”Special Populations” tab_8_content=”1. Pregnancy/Lactation (1) Pregnant women and women who may become pregnant: Ibrutinib may cause damage to the fetus and should not be used by pregnant women. (2) Lactating women: Stop breastfeeding if you need to use the drug during breastfeeding. 2. Elderly No overall difference has been seen in the effectiveness of ibrutinib in elderly patients 65 years of age and older versus younger patients, but elderly patients are more likely to develop pneumonia with the drug. 3. Children The effectiveness and safety of ibrutinib in children has not been established and it is not recommended for use in children. “][/otw_shortcode_tabslayout]